S
Stéphanie Cartalat-Carel
Researcher at Claude Bernard University Lyon 1
Publications - 34
Citations - 2293
Stéphanie Cartalat-Carel is an academic researcher from Claude Bernard University Lyon 1. The author has contributed to research in topics: Temozolomide & Cancer. The author has an hindex of 20, co-authored 34 publications receiving 2104 citations. Previous affiliations of Stéphanie Cartalat-Carel include University of Lyon & HCL Technologies.
Papers
More filters
Journal ArticleDOI
Radiotherapy for glioblastoma in the elderly.
Florence Keime-Guibert,Olivier Chinot,Luc Taillandier,Stéphanie Cartalat-Carel,Marc Frenay,Guy Kantor,Jean-Sébastien Guillamo,Eric Jadaud,Philippe Colin,Pierre-Yves Bondiau,Philippe Menei,Hugues Loiseau,Valérie Bernier,Jérôme Honnorat,Maryline Barrie,Karima Mokhtari,Jean-Jacques Mazeron,Anne Bissery,Jean-Yves Delattre +18 more
TL;DR: Radiotherapy results in a modest improvement in survival, without reducing the quality of life or cognition, in elderly patients with glioblastoma.
Journal ArticleDOI
Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies.
Jérôme Honnorat,Stéphanie Cartalat-Carel,Damien Ricard,Jean-Philippe Camdessanché,Antoine F. Carpentier,Véronique Rogemond,François Chapuis,M. Aguera,Evelyne Decullier,Anne-Marie Duchemin,Francesc Graus,Jean-Christophe Antoine +11 more
TL;DR: It is demonstrated that in patients with paraneoplastic neurological syndromes, the neurological symptoms and survival vary with both the type of associated onco-neural antibody and thetype of tumour.
Journal ArticleDOI
Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
Jaime Gállego Pérez-Larraya,François Ducray,Olivier Chinot,Isabelle Catry-Thomas,Luc Taillandier,Jean-Sébastien Guillamo,Chantal Campello,Annick Monjour,Stéphanie Cartalat-Carel,Maryline Barrie,Aymeri Huchet,Patrick Beauchesne,Mona Matta,Karima Mokhtari,Marie-Laure Tanguy,Jérôme Honnorat,Jean-Yves Delattre +16 more
TL;DR: Temozolomide is associated with improvement of functional status in 33% of patients and appears to increase survival compared with supportive care alone, especially in patients with methylated MGMT promoter.
Journal ArticleDOI
A Tumor Growth Inhibition Model for Low-Grade Glioma Treated with Chemotherapy or Radiotherapy
Benjamin Ribba,Gentian Kaloshi,Mathieu Peyre,Damien Ricard,Vincent Calvez,Michel Tod,Branka Cajavec-Bernard,Ahmed Idbaih,Dimitri Psimaras,Linda Dainese,Johan Pallud,Stéphanie Cartalat-Carel,Jean-Yves Delattre,Jérôme Honnorat,Emmanuel Grenier,François Ducray +15 more
TL;DR: A tumor growth inhibition model able to describe LGG tumor size evolution in patients treated with chemotherapy or radiotherapy is proposed and preliminary results suggest that it can predict treatment response on the basis of pretreatment tumor size data.
Journal ArticleDOI
Gliomatosis Cerebri: A Review of 296 Cases from the ANOCEF Database and the Literature
Sophie Taillibert,Catherine Chodkiewicz,Florence Laigle-Donadey,Massimo Napolitano,Stéphanie Cartalat-Carel,Marc Sanson +5 more
TL;DR: Male population was younger and had a higher incidence of oligodendroglial GC, which may explain their better prognosis than female population, and up-front chemotherapy benefit to some patients and may be prefered to whole brain radiotherapy.